Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Fights To Maintain Aricept Patent Rights While Resuming Development On Next Generation Therapy

This article was originally published in PharmAsia News

Executive Summary

TOKYO - The preliminary injunction against generic company Teva Pharmaceuticals for its abbreviated new drug application pending at U.S. FDA of Japanese company Eisai's Alzheimer's drug Aricept (donepezil) will have very minimal impact on the generic drug industry as a whole, a Japanese patent lawyer told PharmAsia News

You may also be interested in...



Japan’s Eisai Gets Preliminary Injunction Against Teva Aricept Generic

Japan's Eisai has managed to halt Teva Pharmaceutical plans to market a generic of Eisai's Aricept (donepezil) for treating Alzheimer's disease. Eisai said a U.S. district court issued a preliminary injunction against Teva pending the outcome of a patent-infringement suit Eisai filed against the Israeli drug maker. Eisai, whose Aricept patent does not expire until 2010, said the request for the injunction was part of its effort to "protect our intellectual property throughout the world." (Click here for more

Eisai Submits New Formulation For Alzheimer’s Drug Aricept In Japan

TOKYO - Eisai's new oral jelly formulation of Alzheimer's drug Aricept (donepezil) will have no effect on the Japanese company's position in the market, a pharmaceutical analyst and researcher for KBC Securities Japan told PharmAsia News. "It's just a reformulation from an existing product, that already has a lot of patients," analyst Philip Hall said. Eisai announced its application for the new formulation in Japan March 13. The company will not apply for the new formulation in any other country, Eisai Spokeswoman Chie Suzuki told PharmAsia News. "We consider the particular needs of patients in each country and region." "We developed the new formula for this drug in response to the particular needs of patients in Japan," she said. In Japan, Aricept is already available in tablets, fine granules and orally disintegrating tablets. The new formula is the first Alzheimer's disease treatment available in an oral jelly formulation, according to Eisai.

Generic Drug Use To Increase In Japan

 

Related Content

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel